These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 19087950)

  • 21. Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure?
    Erhardt LR
    Ital Heart J; 2003 May; 4 Suppl 2():27S-33S. PubMed ID: 14635367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure.
    Duygu H; Ozerkan F; Zoghi M; Nalbantgil S; Yildiz A; Akilli A; Akin M; Nazli C; Ergene O
    Int J Clin Pract; 2008 Feb; 62(2):228-33. PubMed ID: 17949428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and effectiveness of levosimendan in patients with predominant right heart failure.
    Poelzl G; Zwick RH; Grander W; Metzler B; Jonetzko P; Frick M; Ulmer H; Pachinger O; Roithinger FX
    Herz; 2008 Jul; 33(5):368-73. PubMed ID: 18773157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levosimendan.
    Figgitt DP; Gillies PS; Goa KL
    Drugs; 2001; 61(5):613-27; discussion 628-9. PubMed ID: 11368286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence-based use of levosimendan in different clinical settings.
    De Luca L; Colucci WS; Nieminen MS; Massie BM; Gheorghiade M
    Eur Heart J; 2006 Aug; 27(16):1908-20. PubMed ID: 16682381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levosimendan - a calcium sensitising agent with potential anti-arrhythmic properties.
    Kowalczyk M; Banach M; Lip GY; Kozłowski D; Mikhailidis DP; Rysz J
    Int J Clin Pract; 2010 Jul; 64(8):1148-54. PubMed ID: 20642713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
    Barraud D; Faivre V; Damy T; Welschbillig S; Gayat E; Heymes C; Payen D; Shah AM; Mebazaa A
    Crit Care Med; 2007 May; 35(5):1376-82. PubMed ID: 17414729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies.
    Lilleberg J; Ylönen V; Lehtonen L; Toivonen L
    Scand Cardiovasc J; 2004 May; 38(2):80-4. PubMed ID: 15204232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levosimendan: calcium sensitizer and inodilator.
    Milligan DJ; Fields AM
    Anesthesiol Clin; 2010 Dec; 28(4):753-60. PubMed ID: 21074750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of levosimendan in sepsis and septic shock.
    Pinto BB; Rehberg S; Ertmer C; Westphal M
    Curr Opin Anaesthesiol; 2008 Apr; 21(2):168-77. PubMed ID: 18443483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Levosimendan for treatment of heart failure].
    Yasumura Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():169-72. PubMed ID: 17571380
    [No Abstract]   [Full Text] [Related]  

  • 34. The clinical experience with levosimendan in anesthesiology and in the intensive care unit.
    Cavana M; Pignataro C; Fraticelli A; Mebazaa A
    Ital Heart J; 2003 May; 4 Suppl 2():61S-64S. PubMed ID: 14635372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair.
    Ponschab M; Hochmair N; Ghazwinian N; Mueller T; Plöchl W
    Eur J Anaesthesiol; 2008 Aug; 25(8):627-33. PubMed ID: 18405408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A; Lebrin M; Vaccaro A; Senard JM; Despas F
    J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of levosimendan on acute pulmonary embolism-induced right ventricular failure.
    Kerbaul F; Gariboldi V; Giorgi R; Mekkaoui C; Guieu R; Fesler P; Gouin F; Brimioulle S; Collart F
    Crit Care Med; 2007 Aug; 35(8):1948-54. PubMed ID: 17568324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
    Parissis JT; Adamopoulos S; Antoniades C; Kostakis G; Rigas A; Kyrzopoulos S; Iliodromitis E; Kremastinos D
    Am J Cardiol; 2004 May; 93(10):1309-12. PubMed ID: 15135713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
    Perrone SV; Kaplinsky EJ
    Int J Cardiol; 2005 Sep; 103(3):248-55. PubMed ID: 16098385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.